Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sarafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 4/20 | 0.64 |
| ▸ | TOP2B known ✓ | Q02880 | 3/20 | 0.64 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.50 |
| ▸ | TOP1 known ✓ | P11387 | 1/20 | 0.49 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | BRD4 | O60885 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sarafloxacin SCHEMBL23392485 | 0.99 | ALDH1A1 (0.98) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| Sarafloxacin SCHEMBL311593 | 0.99 | ALDH1A1 (0.98) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| Sarafloxacin SCHEMBL312072 | 0.97 | ALDH1A1 (0.94) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL9443539 | 0.92 | ALDH1A1 (0.85) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL9443495 | 0.92 | ALDH1A1 (0.85) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL9443514 | 0.91 | ALDH1A1 (0.83) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL9044286 | 0.91 | ALDH1A1 (0.83) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL9443455 | 0.91 | ALDH1A1 (0.83) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL11017466 | 0.91 | ALDH1A1 (0.83) | ALDH1A1KDM4ELMNAHSD17B10HPGD | |
| SCHEMBL9443467 | 0.89 | ALDH1A1 (0.80) | ALDH1A1KDM4ELMNAHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 729 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120022801-A | Salad dressing raw materials mixing arrangement | 内蒙古安洲药业有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119684207-A | Quinolinone compound, preparation method and application thereof in preventing and treating plant diseases | 广西田园生化股份有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-114965764-B | Diagnosis and treatment of constipation | 陕西安宁云生生物技术有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2023222083-A1 | CONSTIPATION DIAGNOSIS AND TREATMENT | 陕西安宁云生生物技术有限公司 | 2023-11-23 | — | — | WO | claimed |
| CN-116440782-A | Preparation device and process of high-stability sarafloxacin hydrochloride soluble powder | 江苏欧克动物药业有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-114814013-B | Method for rapidly screening unknown chemical hazard residues in aquatic products based on high-resolution mass spectrum database | 中国海洋大学 | 2023-06-02 | — | — | CN | claimed |
| CN-114965764-A | Diagnosis and treatment of constipation | 陕西安宁云生生物技术有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-111521712-B | Liquid chromatography analysis method for simultaneously determining contents of 3 sulfonamides and 4 quinolones | 重庆方通动物药业有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-114053229-B | Sarafloxacin hydrochloride water-soluble granules and preparation method thereof | 山东国邦药业有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-112662664-B | Screening method of specifically-bound sarafloxacin hydrochloride aptamer | 北京化工大学 | 2022-04-19 | — | — | CN | claimed |
| EP-1656018-A4 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | INNOZEN INC (US) | 2008-07-23 | — | — | EP | claimed |
| CN-101108835-A | Method of manufacturing high purity hydrochloric acid sarafloxacin | LUOYANG PULIKE BIOLOGY ENGINEE (CN) | 2008-01-23 | — | — | CN | claimed |
| CN-101015523-A | Compound sarafloxacin hydrochloride injection, preparing method and use thereof | TIANJIN SHENGJI GROUP CO LTD (CN) | 2007-08-15 | — | — | CN | claimed |
| CN-1965835-A | Sarafloxacin hydrochloride solution containing hexacyclic ring water for livestock | TIANJIN RINGTOP BIOTECHNOLOGY (CN) | 2007-05-23 | — | — | CN | claimed |
| EP-1656018-A1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | Innozen, Inc. (US) | 2006-05-17 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050136096-A1 | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2005-06-23 | — | — | US | claimed |
| WO-2005018323-A1 | EDIBLE FILMS FOR ADMINISTRATION OF MEDICAMENTS TO ANIMALS | INNOZEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |